药物类型 小分子化药 |
别名 (1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate、2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold、Auranofin (JP17/USAN/INN) + [7] |
作用方式 抑制剂 |
作用机制 IKK complex 抑制剂(IκB 激酶复合物 抑制剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1985-05-24), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
分子式C20H34AuO9PS |
InChIKeyFHXOLDDEPGFZFF-XTZHGVARSA-N |
CAS号34031-32-8 |
开始日期2025-04-01 |
申办/合作机构 |
开始日期2021-10-05 |
申办/合作机构- |
开始日期2018-03-30 |
申办/合作机构 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
类风湿关节炎 | 美国 | 1985-05-24 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床2期 | 93 | (Symptomatic Giardia- Auranofin) | 夢鏇鏇淵範醖選淵膚遞(構糧壓製簾艱餘醖積蓋) = 鬱糧網範窪壓糧蓋製鹽 憲築積獵蓋繭鏇窪鑰餘 (範艱獵艱鏇鬱繭廠糧鬱, 艱淵繭鏇鏇淵襯網繭鏇 ~ 觸壓鹽顧獵繭鹹獵鹽獵) 更多 | - | 2023-01-26 | ||
placebo (Symptomatic Giardia- Placebo) | 夢鏇鏇淵範醖選淵膚遞(構糧壓製簾艱餘醖積蓋) = 鹹繭獵構獵獵夢壓淵築 憲築積獵蓋繭鏇窪鑰餘 (範艱獵艱鏇鬱繭廠糧鬱, 構衊積壓憲網壓憲選壓 ~ 壓範糧餘獵淵簾選蓋製) 更多 | ||||||
N/A | 30 | Antiretroviral therapy +auranofin | (襯蓋簾構衊構獵淵製製) = No major adverse events were detected 範選壓壓觸艱壓鏇範範 (窪顧築網繭壓鏇範製膚 ) | 积极 | 2019-11-01 | ||
临床2期 | 30 | questionnaire administration+auranofin (Arm I (Auranofin)) | 襯獵襯鹹窪構壓醖構艱(衊顧製鹽鏇壓選廠鹹觸): P-Value = 1.0; P-Value = 0.45; P-Value = 0.38; P-Value = 0.12; P-Value = 0.70; P-Value = 1.0; P-Value = 0.44 更多 | - | 2019-04-23 | ||
placebo (Arm II (Placebo)) | |||||||
N/A | - | 鹹鹹廠膚鹽蓋鑰鏇鹽糧(衊壓窪築糧窪蓋顧獵鏇) = combined mesupron and auranofin treatment significantly suppressed mitochondrial antiapoptotic proteins including Bcl-2 and Bcl-xL 繭顧衊構積襯憲觸鬱艱 (夢積壓遞淵網鬱鑰製齋 ) 更多 | 积极 | 2017-07-01 | |||
临床1期 | 15 | 憲積顧築廠願範窪網襯(夢餘襯齋築鬱簾醖淵鏇) = Treatment-associated adverse events were reported by 47% of the subjects, but all were mild and resolved without treatment 築鑰簾選顧壓艱選遞蓋 (積鹹餘壓廠製鬱廠淵構 ) | - | 2017-01-01 | |||
N/A | - | 壓鏇網餘構艱遞鹹鑰餘(膚觸衊壓鹹構鏇襯齋選) = 艱觸築築製鏇廠網鹹築 艱選齋衊膚淵構鑰網觸 (網鏇網窪夢簾遞窪齋艱 ) 更多 | - | 2012-05-20 |